ClinicalTrials.gg
CompletedNCT04949841DELTA 3Updated Apr 8, 2025Results posted

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

A Phase 3 interventional study of Delgocitinib in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 95 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
801
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
Largest of 12
801 · median 178
Started
2021
with 2 others
Phase 3
7 of 13
none open now
Registered
8th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 8th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The purpose of this extension trial is to evaluate the long-term safety of delgocitinib.

Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.

Read the detailed description

Subject who completed 16 weeks of treatment with delgocitinib cream 20 mg/g or vehicle cream twice daily in trials DELTA 1 or DELTA 2 will be offered to roll-over to this extension trial.

Subjects will be treated with delgocitinib cream 20 mg/g twice daily only if they need it to control their chronic hand eczema. In the periods when the disease is controlled, no treatment will be administered.

Clinic visits every 4 weeks are planned (with the possibility of unscheduled visits) to investigate safety and efficacy of treatment, as well as its effect on patient-reported outcomes (PROs).

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have met eligibility criteria at screening and baseline in the parent trial (DELTA 1 or DELTA 2).
  • Participants must have completed the treatment period in the parent trial (to be assessed at baseline visit in this extension trial).
  • Participants must have complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator.
  • A woman of must use an acceptable method of throughout the trial up until the end-of-treatment/early termination visit.

Exclusion criteria

Exclusion Criteria:

  • Participants who prematurely discontinued treatment with IMP or initiated rescue medication in the parent trial.
  • Participants who experienced any adverse event (AE) during participation in the parent trial, which precludes further treatment with delgocitinib cream 20 mg/g in the judgement of the investigator.
  • Any medical or psychiatric condition that could put the participant at undue risk by participating in the trial, or which, by the investigator's judgment, makes the participant inappropriate for the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
801 participants (actual)

Study arms

  • Experimental
    As-needed treatment with delgocitinib

    Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.

    Drug: Delgocitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events From Baseline up to Week 38

    An AE will be considered treatment emergent if it started after the baseline visit

    Time frame: From baseline up to Week 38

Secondary outcomes

  1. Number of Participants With IGA-CHE Score at Each Scheduled Visit From Baseline up to Week 36

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

    Time frame: From baseline up to Week 38

  2. Number of Participants With IGA-CHE Score of 0 (Clear) or 1 (Almost Clear) at Each Scheduled Visit From Baseline up to Week 36.

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

    Time frame: From baseline up to Week 38

  3. HECSI Score at Each Scheduled Visit From Baseline up to Week 36

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).

    Time frame: From baseline up to Week 38

  4. Number of Participants With HECSI-75 at Each Scheduled Visit From Baseline up to Week 36

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.

    Time frame: From baseline up to Week 38

  5. Number of Participants With HECSI-90 at Each Scheduled Visit From Baseline up to Week 36

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.

    Time frame: From baseline up to Week 38

07

Results

Posted Jan 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneAs-needed Treatment With Delgocitinib
Started801
Completed664
Not completed137
Withdrew: Adverse event7
Withdrew: Death1
Withdrew: Withdrawal by subject52
Withdrew: Pregnancy4
Withdrew: Lost to follow-up9
Withdrew: Lack of efficacy55
Withdrew: Various reasons9

Outcome measures

PrimaryNumber of Treatment-emergent Adverse Events From Baseline up to Week 38

An AE will be considered treatment emergent if it started after the baseline visit

Time frame:
From baseline up to Week 38
Reported as:
Number · events
Number of Treatment-emergent Adverse Events From Baseline up to Week 38
eventsAs-needed Treatment With Delgocitinib
Number of Treatment-emergent Adverse Events From Baseline up to Week 381238
SecondaryNumber of Participants With IGA-CHE Score at Each Scheduled Visit From Baseline up to Week 36

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

Time frame:
From baseline up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Score at Each Scheduled Visit From Baseline up to Week 36
ParticipantsAs-needed Treatment With Delgocitinib
At baseline : 0-Clear77
At baseline : 1- Almost Clear83
At baseline : 2- Mild345
At baseline : 3- Moderate243
At baseline : 4- Severe53
Week 4 : 0-Clear58
Week 4 : 1- Almost Clear76
Week 4 : 2- Mild436
Week 4 : 3- Moderate189
Week 4 : 4- Severe28
Week 8 : 0-Clear73
Week 8 : 1- Almost Clear82
Week 8 : 2- Mild413
Week 8 : 3- Moderate167
Week 8 : 4- Severe25
Week 12 : 0-Clear79
Week 12 : 1- Almost Clear76
Week 12 : 2- Mild414
Week 12 : 3- Moderate152
Week 12 : 4- Severe18
Week 16 : 0-Clear79
Week 16 : 1- Almost Clear77
Week 16 : 2- Mild407
Week 16 : 3- Moderate147
Week 16 : 4- Severe13
Week 20 : 0-Clear72
Week 20 : 1- Almost Clear90
Week 20 : 2- Mild401
Week 20 : 3- Moderate123
Week 20 : 4- Severe19
Week 24 : 0-Clear65
Week 24 : 1- Almost Clear67
Week 24 : 2- Mild415
Week 24 : 3- Moderate118
Week 24 : 4- Severe15
Week 28 : 0-Clear68
Week 28 : 1- Almost Clear79
Week 28 : 2- Mild408
Week 28 : 3- Moderate109
Week 28 : 4- Severe8
Week 32 : 0-Clear71
Week 32 : 1- Almost Clear67
Week 32 : 2- Mild395
Week 32 : 3- Moderate118
Week 32 : 4- Severe12
Week 36 : 0-Clear115
Week 36 : 1- Almost Clear124
Week 36 : 2- Mild300
Week 36 : 3- Moderate111
Week 36 : 4- Severe13
SecondaryNumber of Participants With IGA-CHE Score of 0 (Clear) or 1 (Almost Clear) at Each Scheduled Visit From Baseline up to Week 36.

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

Time frame:
From baseline up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With IGA-CHE Score of 0 (Clear) or 1 (Almost Clear) at Each Scheduled Visit From Baseline up to Week 36.
ParticipantsAs-needed Treatment With Delgocitinib
Baseline160
Week 4134
Week 8155
Week 12155
Week 16156
Week 20162
Week 24132
Week 28147
Week 32138
Week 36239
SecondaryHECSI Score at Each Scheduled Visit From Baseline up to Week 36

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).

Time frame:
From baseline up to Week 38
Reported as:
Mean · score on a scale
HECSI Score at Each Scheduled Visit From Baseline up to Week 36
score on a scaleAs-needed Treatment With Delgocitinib
Baseline30.8 ± 36.5
Week 424.3 ± 27.2
Week 821.4 ± 25.3
Week 1220.2 ± 23.9
Week 1617.9 ± 21.1
Week 2017.8 ± 22.5
Week 2417.7 ± 19.6
Week 2816.6 ± 19.0
Week 3216.9 ± 20.0
Week 3615.4 ± 20.6
SecondaryNumber of Participants With HECSI-75 at Each Scheduled Visit From Baseline up to Week 36

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.

Time frame:
From baseline up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With HECSI-75 at Each Scheduled Visit From Baseline up to Week 36
ParticipantsAs-needed Treatment With Delgocitinib
At baseline347
Week 4391
Week 8415
Week 12411
Week 16432
Week 20438
Week 24409
Week 28414
Week 32411
Week 36452
SecondaryNumber of Participants With HECSI-90 at Each Scheduled Visit From Baseline up to Week 36

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.

Time frame:
From baseline up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With HECSI-90 at Each Scheduled Visit From Baseline up to Week 36
ParticipantsAs-needed Treatment With Delgocitinib
At baseline207
Week 4195
Week 8224
Week 12222
Week 16229
Week 20239
Week 24204
Week 28236
Week 32220
Week 36291

Adverse events

Collected over From baseline to week 36. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
As-needed Treatment With Delgocitinib3/801 (0.4%)27/801 (3.4%)329/801 (41.1%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventAs-needed Treatment With Delgocitinib
Hand dermatitisSkin and subcutaneous tissue disorders2/801
Myocardial infarctionCardiac disorders1/801
Abdominal incarcerated herniaGastrointestinal disorders1/801
Abdominal pain upperGastrointestinal disorders1/801
Food poisoningGastrointestinal disorders1/801
DeathGeneral disorders1/801
CholecystitisHepatobiliary disorders1/801
CholelithiasisHepatobiliary disorders1/801
Contrast media allergyImmune system disorders1/801
AppendicitisInfections and infestations1/801
Most frequent other events
Most frequent other events
EventAs-needed Treatment With Delgocitinib
COVID-19Infections and infestations134/801
NasopharyngitisInfections and infestations128/801
Upper respiratory tract infectionInfections and infestations32/801
Hand dermatitisSkin and subcutaneous tissue disorders30/801
InfluenzaInfections and infestations28/801
HeadacheNervous system disorders22/801
Back painMusculoskeletal and connective tissue disorders19/801
EczemaSkin and subcutaneous tissue disorders17/801

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)As-needed Treatment With Delgocitinib
<=18 years0
Between 18 and 65 years735
>=65 years66
Age, Continuous
Age, Continuous(years)As-needed Treatment With Delgocitinib
Mean45 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)As-needed Treatment With Delgocitinib
Female512
Male289
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)As-needed Treatment With Delgocitinib
Hispanic or Latino21
Not Hispanic or Latino752
Unknown or Not Reported28
Region of Enrollment
Region of Enrollment(participants)As-needed Treatment With Delgocitinib
Canada162
Netherlands16
Belgium19
Denmark20
Poland180
Italy40
United Kingdom23
France68
Germany215
Spain58
08

Study locations

95 sites
  • LEO Investigational Site
    Brussel, 1000, Belgium
  • LEO Investigational Site
    Gent, 9000, Belgium
  • LEO Investigational Site
    Kortrijk, 8500, Belgium
  • LEO Investigational Site
    Leuven, 3000, Belgium
  • LEO Investigational Site
    Loverval, 6280, Belgium
  • LEO Investigational Site
    Maldegem, 9990, Belgium
  • LEO Investigational Site
    Calgary, Alberta T2J 7E1, Canada
  • LEO Investigational Site
    Calgary, Alberta T3E 0B2, Canada
  • LEO Investigational Site
    Edmonton, Alberta T5J 3S9, Canada
  • LEO Investigational Site
    Edmonton, Alberta T6G 1C3, Canada
  • LEO Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • LEO Investigational Site
    Vancouver, British Columbia V6 4E1, Canada
  • LEO Investigational Site
    Fredericton, New Bruswick E3B 1G9, Canada
  • LEO Investigational Site
    Ajax, Ontario L1S 7K8, Canada
  • LEO Investigational Site
    Cobourg, Ontario K9A 4J9, Canada
  • LEO Investigational Site
    Etobicoke, Ontario M8X 1Y9, Canada
  • LEO Investigational Site
    Hamilton, Ontario L8S 1G5, Canada
  • LEO Investigational Site
    Kingston, Ontario K7L 2V7, Canada
  • LEO Investigational Site
    London, Ontario N6A 3H7, Canada
  • LEO Investigational Site
    Markham, Ontario L3P 1X3, Canada
  • LEO Investigational Site
    Toronto, Ontario M2M 4J5, Canada
  • LEO Investigational Site
    Toronto, Ontario M3H 5Y8, Canada
  • LEO Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • LEO Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • LEO Investigational Site
    Montreal, Quebec H2X 2V1, Canada
  • LEO Investigational Site
    Aarhus N, 8200, Denmark
  • LEO investigational Site
    Copenhagen, 2400, Denmark
  • LEO Pharma Investigational Site
    Hellerup, 2900, Denmark
  • LEO Investigational Site
    Bordeaux, 33000, France
  • LEO Investigational Site
    Dijon, 21000, France
  • LEO Investigational Site
    Le Mans, 72037, France
  • LEO Investigational Site
    Lille, 5900, France
  • LEO Investigational Site
    Martigues, 13500, France
  • LEO Pharma Investigational Site
    Nantes, 44093, France
  • LEO Investigational Site
    Nice, 06000, France
  • LEO Investigational Site
    Nice, 06202, France
  • LEO Investigational Site
    Paris, 75014, France
  • LEO Investigational Site
    Reims, 51100, France
  • LEO Investigational Site
    Toulouse, 31000, France
  • LEO Investigational Site
    Aachen, 52074, Germany
  • LEO Investigational Site
    Bad Bentheim, 48455, Germany
  • LEO Investigational Site
    Berlin, 10115, Germany
  • LEO Investigational Site
    Dresden, 01307, Germany
  • LEO Investigational Site
    Frankfurt am Main, 60590, Germany
  • LEO Investigational Site
    Friedrichshafen, 88045, Germany
  • LEO Investigational Site
    Gera, 07548, Germany
  • LEO Investigational Site
    Göttingen, 37073, Germany
  • LEO Investigational Site
    Hamburg, 22391, Germany
  • LEO Investigational Site
    Hannover, 30159, Germany
  • LEO Investigational Site
    Hassfurt, 97437, Germany
  • LEO Investigational Site
    Jena, 07743, Germany
  • LEO Investigational Site
    Luebeck, 23538, Germany
  • LEO Investigational Site
    Mahlow, 15831, Germany
  • LEO Investigational Site
    Mainz-Bretzenheim, 55128, Germany
  • LEO Pharma Investigational Site
    Memmingen, 87700, Germany
  • LEO Investigational Site
    München, 80802, Germany
  • Leo Investigational Site
    Münster, 48149, Germany
  • LEO Investigational Site
    Osnabrück, 49074, Germany
  • LEO Investigational Site
    Stuttgart, 70178, Germany
  • LEO Investigational Site
    Brescia, 25123, Italy
  • LEO Investigational Site
    L'Aquila, 67100, Italy
  • LEO Investigational Site
    Rome, 00168, Italy
  • LEO Investigational Site
    Vicenza, 36100, Italy
  • LEO Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • LEO Investigational Site
    Bergen Op Zoom, 4614 VT, Netherlands
  • LEO Investigational Site
    Groningen, 9713 GZ, Netherlands
  • LEO Investigational Site
    Hoofddorp, 2134 TM, Netherlands
  • LEO Investigational Site
    Utrecht, 3584 CX, Netherlands
  • LEO Investigitional Site
    Białystok, 15-375, Poland
  • LEO Investigational Site
    Białystok, 15-794, Poland
  • LEO Investigational Site
    Gdansk, 80-546, Poland
  • LEO Investigational Site
    Kraków, 30-033, Poland
  • LEO Investigational Site
    Kraków, 31-011, Poland
  • LEO Investigational Site
    Lublin, 20-081, Poland
  • LEO Investigational Site
    Lublin, 20-406, Poland
  • LEO Investigational Site
    Osielsko, 86-031, Poland
  • LEO Pharma Investigational Site
    Rzeszów, 35-055, Poland
  • LEO Investigational Site
    Warsaw, 02-953, Poland
  • LEO Investigational Site
    Warsaw, 02-962, Poland
  • LEO Investigational Site
    Warszawa, 02-507, Poland
  • LEO Investigational Site
    Warszawa, 02-625, Poland
  • LEO Investigational Site
    Wrocław, 50-566, Poland
  • LEO Investigational Site
    Wrocław, 51-318, Poland
  • LEO Investigational Site
    Łódź, 90-436, Poland
  • LEO Investigational Site
    Alicante, 03010, Spain
  • LEO Investigational Site
    Badalona, 08915, Spain
  • LEO Investigitional Site
    Barcelona, 08041, Spain
  • LEO Investigational Site
    Bilbao, 48013, Spain
  • LEO Investigational Site
    Madrid, 28031, Spain
  • LEO Investigational Site
    Mieres, 33611, Spain
  • LEO Investigational Site
    Sevilla, 41009, Spain
  • LEO Investigational Sites
    Redhill, Surrey RH1 5RH, United Kingdom
  • LEO Investigational Site
    London, SE1 7EH, United Kingdom
  • LEO Investigational Site
    Middlesborough, TS4 3BW, United Kingdom
  • LEO Investigational Site
    Salford, M6 8HD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Sep 2023, 24 months.

Results were first posted in Jan 2025, 1 year 4 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 2, 2021
StartActual
Aug 23, 2021
Primary completionActual
Sep 18, 2023
CompletionActual
Sep 18, 2023
Results first posted
Jan 20, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04949841
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Aug 23, 2021
Primary completion
Sep 18, 2023
Completion
Sep 18, 2023
Results posted
Jan 20, 2025
Last update
Apr 8, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion